ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 157.3 DKK -2.48%
Market Cap: 34.8B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note

Gross Margin
ALK-Abello A/S

63.9%
Current
62%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.9%
=
Gross Profit
3.4B
/
Revenue
5.4B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
DK
ALK-Abello A/S
CSE:ALK B
34.8B DKK
64%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
69%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
77%
CH
Roche Holding AG
SIX:ROG
199.4B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
161.4B GBP
82%
CH
Novartis AG
SIX:NOVN
170.9B CHF
75%
US
Pfizer Inc
NYSE:PFE
149.4B USD
71%
Country DK
Market Cap 34.8B DKK
Gross Margin
64%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.8T DKK
Gross Margin
85%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 199.4B CHF
Gross Margin
73%
Country UK
Market Cap 161.4B GBP
Gross Margin
82%
Country CH
Market Cap 170.9B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
34.8B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
153.16 DKK
Overvaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.9%
=
Gross Profit
3.4B
/
Revenue
5.4B
What is the Gross Margin of ALK-Abello A/S?

Based on ALK-Abello A/S's most recent financial statements, the company has Gross Margin of 63.9%.